Comparative efficacy, acceptability and cost effectiveness of pharmacological treatments for depression in adults with bipolar disorder

[1]  R. Porter,et al.  Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders , 2015, The Australian and New Zealand journal of psychiatry.

[2]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[3]  T. Ketter,et al.  Pharmacotherapy for bipolar depression: comparative efficacy and acceptability is in the eye of the beholder , 2015, Evidence-Based Mental Health.

[4]  E. Paykel,et al.  Differential effects of depression and mania symptoms on social adjustment: prospective study in bipolar disorder , 2013, Bipolar disorders.

[5]  S. Dilsaver.  An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. , 2011, Journal of affective disorders.

[6]  T. Barnes.  Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology , 2011, Journal of psychopharmacology.

[7]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.

[8]  E. Holmes,et al.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology , 2009, Journal of psychopharmacology.

[9]  W. Nolen,et al.  The societal costs and quality of life of patients suffering from bipolar disorder in the Netherlands , 2004, Acta psychiatrica Scandinavica.

[10]  J. Markowitz,et al.  The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.

[11]  L. Judd,et al.  A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. , 2003, Archives of general psychiatry.

[12]  John A. Rice,et al.  The long-term natural history of the weekly symptomatic status of bipolar I disorder. , 2002, Archives of general psychiatry.

[13]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[14]  D J Spiegelhalter,et al.  Bayesian methods for cluster randomized trials with continuous responses. , 2001, Statistics in medicine.

[15]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[16]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[17]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[18]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[19]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[20]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making 1: Introduction. Medical Decision Making, , 2013 .

[21]  Alex J. Sutton,et al.  Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials. , 2013 .

[22]  H. Grunze,et al.  [Annual costs of bipolar disorders in Germany]. , 2004, Der Nervenarzt.